MedNet

Dry Eye Disease: Current and Emerging Novel Tear Stimulating Therapies for Improved Outcomes
2025-04-12 08:00 - 17:00 (America/New_York)
Take Me to the Event Registration

EVENT Summary
Dates
Saturday, April 12, 2025, 10:00 AM ET, 9:00 AM CT, 8:00 AM MT, and 7:00 AM PT
Location
Virtual
Target Audience
Ophthalmologists, optometrists, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with dry eye disease (DED)
Format
Zoom Webinar
Credits
1.25 / AMA PRA Category 1 Credit(s)TM
1.25 / COPE CE Credits
Cost
Free

Program Description
Click to Go to the Event Registration
This program will provide up-to-date, evidence-based information on DED, evaluations, and emerging therapies. The activity will focus on:
Pathophysiology of DED – The pathogenesis of MGD and DED can be described as a ‘vicious circle’; the underlying pathophysiological mechanisms of DED and MGD interact, resulting in a ‘double vicious circle’

The vicious circle of DED
Dual “Vicious Circle” of DED and MGD
Factors Contributing to DED

Preservatives in topicals contribute to DED
DED in patients after refractive or cataract surgery
DED in postmenopausal women
DED in patients with autoimmune disorders

Available Treatment Options for MGD-Associated DED – Treatment for MGD-associated DED encompasses a wide range of approaches, such as:

Preservative-free Artificial Tears,
Warming and Eyelid Compression,
Thermal Pulsation,
LipiFlow Thermal Pulsation System,
Intense Pulsed Light (IPL) Therapy,
Topical and oral Azithromycin,
Intraductal probing,
Hormone Replacement Therapy (HRT) to alleviate DED in menopausal women,
Topical anti-inflammatory therapies, such as tacrolimus and cyclosporin A for DED in patients with autoimmune diseases

Novel Tear Stimulating Therapies
New treatment options for DED – Several pharmacologic agents with novel mechanisms of action for treating DED are under development.

Varenicline nasal spray
Perfluorohexyloctane ophthalmic solution (Miebo®)
Lifitegrast
Reproxalap
Water-free topical cyclosporine, 0.1% and 0.5%
AZR-MD-001 (selenium sulfide ophthalmic ointment)
NOV03 (perfluorohexyloctane)
Lotilaner (TP-03)

Agenda
• Discuss the pathophysiology and factors contributing to DED such as preservatives in topicals, refractive or cataract surgery, menopause, and autoimmune diseases – Neal Guymon, OD
• Discuss the real-world evidence surrounding available and new tear-stimulating therapies to improve patient outcomes of individuals with DED – Eric D. Donnenfeld, MD
Intended Audience
Ophthalmologists, optometrists, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with dry eye disease (DED).
Commercial Supporter
Supported by an unrestricted educational grant from Oyster Point
Learning Objectives

Summarize the pathophysiology and factors contributing to DED, such as preservatives in topicals, refractive or cataract surgery, menopause, and autoimmune diseases
Assess real-world evidence surrounding available and new tear-stimulating therapies to improve patient outcomes of individuals with DED

Accredited Providers
Amedco and MedNet have collaborated to design and execute this activity.

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.
Physicians (ACCME) Credit Designation
Amedco LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Optometrists Credit
This activity, COPE course 97133-TD, is accredited by COPE for continuing education for optometrists. COPE Activity ID#130386.
MedNet designates this activity for a maximum of 1.25 COPE credits.
Additional Credit Information
Physician Assistants
PAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. 1.25 hours.
Disclosures of Relationships with Ineligible Companies Policy
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.
Planners’ and Managers’ Disclosures
All relevant relationships have been reviewed and mitigated.
Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.
Faculty

Neal Guymon, OD
Optometrist
Summit EyeCare
Idaho Falls, ID

Eric D. Donnefeld, MD
Clinical Professor of Ophthalmology
New York University Langone Medical Center
Ophthalmic Consultants of Long Island
New York, NY
Instructions/Technical Requirements
Hardware: An internet-enabled computer, smartphone, tablet, or other mobile device with audio and internet capabilities.
Software: Installation of software like Zoom may be necessary.
Cost
There are no fees for participating and receiving CME and COPE credit for this activity.
Contact
Brian Waggoner
Program Manager
MedNet
brianw@mmhus.net

Ocular Surface Disease: Pathophysiology, Evaluation, Management with Topical Agents, and Neuromodulation
2025-03-01
March 8, 2025

Take Me to the Event Registration

EVENT Summary
Dates
Saturday, March 8, 2025, 10:00 AM ET, 9:00 AM CT, 8:00 AM MT, and 7:00 AM PT
Location
Virtual
Target Audience
Ophthalmologists, optometrists, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with ocular surface disease
Format
Zoom Webinar
Credits
1.25 / AMA PRA Category 1 Credit(s)TM
1.25 / COPE CE Credits
Cost
Free
Program Description
Click to Go to the Event Registration
This program will provide up-to-date, evidence-based information on pathophysiology, evaluation, topical agents, and neuromodulation in managing OSD. The activity will focus on:

Pathophysiology – Normal ocular surface physiology, including the role of the lacrimal functional unit in stimulating the lacrimal gland, meibomian glands, and goblet cells.
Risk factors for OSD – Contact lens wear, ocular surgery, extensive digital device use, and eye makeup.
Evaluation – Symptom questionnaires, tear breakup time, tear volume assessment, and ocular surface staining
Management of OSD with Artificial Tears – Artificial tear formulations and benefits in managing different dry eye sub-types

Active and inactive ingredients, including the role of inactive ingredients in optimizing delivery and retention time.
Preserved vs preservative-free (unit dose vs multi-dose dispensing methods)
Lipid-enhanced vs. non-lipid-enhanced.
The efficacy and safety profile of short-term and chronic treatment options for inflammatory dry eye.

Neuromodulation in OSD – Neural network that monitors the ocular surface environment and regulates tear secretion.

Afferent sensory fibers in the nasal mucosa and ocular surface (nicotinic muscarinic receptors and TRP receptors).
Efferent parasympathetic pathways and targets (lacrimal gland, meibomian glands, and goblet cells.
Neurotrophic Keratopathy (NK) – Clinically, stage 1 NK is similar to moderate-to-severe dry eye disease (DED) or many other epitheliopathies
Cenegermin is a recombinant human nerve growth factor (rh-NGF) that supports corneal reinnervation.

Agenda
• Overview of the pathophysiology, risk factor, and evaluation of ocular surface disease (OSD) – Sarah B. Sunshine, MD
• Discuss the data on artificial tear formulations and neuromodulation in managing OSD – TBD
Intended Audience
Ophthalmologists, optometrists, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with ocular surface disease
Commercial Supporter
Supported by an unrestricted educational grant from Dompé US Inc.
Learning Objectives
Summarize the pathophysiology, risk factor, and evaluation of ocular surface disease
Interpret data on artificial tear formulations and neuromodulation in managing ocular surface disease

Accredited Providers
Amedco and MedNet have collaborated to design and execute this activity.

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.
Physicians (ACCME) Credit Designation
Amedco LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Optometrists Credit
This activity, COPE Activity Number 130237, is accredited by COPE for continuing education for optometrists.
MedNet designates this activity for a maximum of 1.25 COPE credits.
Additional Credit Information
Physician Assistants
PAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. 1.25 hours.
Disclosures of Relationships with Ineligible Companies Policy
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.
Planners’ and Managers’ Disclosures
All relevant relationships have been reviewed and mitigated.
Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Faculty

Sarah B. Sunshine, MD
Assistant Professor
Ophthalmology, University of Maryland and Greenebaum Comprehensive Cancer
Baltimore, MD
Instructions/Technical Requirements
Hardware: An internet-enabled computer, smartphone, tablet, or other mobile device with audio and internet capabilities.
Software: Installation of software like Zoom may be necessary.
Cost
There are no fees for participating and receiving CME and COPE credit for this activity.
Contact
Brian Waggoner
Program Manager
MedNet
brianw@mmhus.net

Cataracts: Advances in Imaging, Intraocular Lenses, and Surgical Procedures
2025-01-25
January 25, 2025

Take Me to the Event Registration

EVENT Summary
Dates
Saturday, January 25, 2025, 10:00 AM ET, 9:00 AM CT, 8:00 AM MT, and 7:00 AM PT
Location
Virtual
Target Audience
Ophthalmologists, optometrists, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with cataracts.
Format
Zoom Webinar
Credits
1.25 / AMA PRA Category 1 Credit(s)TM
1.25 / COPE CE Credits
Cost
Free
Program Description
Click to Go to the Event Registration
The activity will focus on:
Types of Cataracts

Age-related cataracts
Congenital cataracts
Secondary cataracts
Traumatic cataracts

Imaging for cataracts

Preoperative imaging preparation of the ocular surface
Intraoperative imaging in cataract surgery
Intraoperative imaging in white cataracts
Intraoperative imaging in posterior polar cataracts
Intraoperative imaging of corneal wound architecture

Surgical Options for cataracts

Ultrasound-based phacoemulsification
Monofocal IOLs
Bifocal IOLs
Trifocal IOLs

Extended Depth of Focus (EDOF) IOLs

Light-Adjustable IOLs
Toric Monovision IOLs
Toric Multifocal IOLs

Agenda

Overview of the types of cataracts, preoperative, and intraoperative imaging of cataracts – William Waldrop, MD
Discuss the innovations in cataract surgery to provide better visual outcomes and safety – Michele D. Lee, MD

Intended Audience
Ophthalmologists, optometrists, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with cataracts.
Commercial Supporter
Supported by an educational grant from Alcon Vision and Johnson & Johnson Surgical Vision.
Learning Objectives

Summarize the types of cataracts, preoperative, and intraoperative imaging of cataracts
Outline the innovations in cataract surgery to provide better visual outcomes and safety

Accredited Providers
Amedco and MedNet have collaborated to design and execute this activity.

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.
Physicians Credit Designation
Amedco LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Optometrists Credit
Amedco is accredited by COPE to provide continuing education to optometrists.
Amedco designates this activity for a maximum of 1.25 COPE credits.
Additional Credit Information
Physician Assistants
PAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. 1.25 hours.
Disclosures of Relationships with Ineligible Companies Policy
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.
Planners’ and Managers’ Disclosures
All relevant relationships have been reviewed and mitigated.
Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Faculty

Michele Lee, MD
Cornea, Cataract, Refractive Surgeon
Tozer Lee Eye Center
Scottsdale, AZ

William Waldrop, MD
Assistant Professor
Department of Ophthalmology
UT Southwestern Medical Center
Dallas, TX
Instructions/Technical Requirements
Hardware: An internet-enabled computer, smartphone, tablet, or other mobile device with audio and internet capabilities.
Software: Installation of software like GoToWebinar may be necessary.
Cost
There are no fees for participating and receiving CME and COPE credit for this activity.
Contact
Brian Waggoner
Program Manager
MedNet
brianw@mmhus.net

Advances in Blood-based Biomarkers and Disease Modifying Anti-Amyloid Antibody Therapies for Early-Stage Alzheimer’s Disease
2024-08-03
August 3, 2024
Take Me to the Event Registration

EVENT Summary
Dates
Saturday, August 3, 2024, 10:00 AM ET, 9:00 AM CT, 8:00 AM MT, and 7:00 AM PT
Location
Virtual
Target Audience
Neurologists, nurse practitioners, and physician assistants involved in Alzheimer’s disease patient care.
Format
Zoom Webinar
Credits
1.50 / AMA PRA Category 1 Credit(s)TM
1.50 / ANCC Contact Hours
Cost
Free
Program Description
Click to Go to the Event Registration
This webinar provides an up-to-date, evidence-based information on pathophysiology, biomarkers, and disease-modifying drugs in treating Alzheimer’s disease (AD).
Agenda

Discuss the blood-based biomarkers in diagnosing early-stage Alzheimer’s disease (AD) and its utility in the prevention – Gary Small, MD
Discuss clinical trial data on safety-efficacy profiles of approved and investigational disease-modifying anti-amyloid antibody therapies in managing early AD – Paul Schulz MD

Intended Audience
Neurologists, nurse practitioners, and physician assistants involved in Alzheimer’s disease patient care.
Commercial Supporter
Supported by an educational grant from Eisai, Inc.
Learning Objectives

Summarize the pathophysiology and the clinical presentation of Alzheimer’s disease (AD).
Assess the blood-based biomarkers in diagnosing early-stage AD and its utility in the prevention.
Identify strategies to optimize disease-modifying anti-amyloid antibody (AAA) therapies in managing patients with early-stage AD.

Accredited Providers
Amedco and MedNet have collaborated to design and execute this activity.

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.
Physicians (ACCME) Credit
Designation Statement
Amedco LLC designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses (ANCC) Credit
Designation Statement
Amedco LLC designates this activity for a maximum of 1.50 ANCC contact hours.
Additional Credit Information
Physician Assistants
PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. 1.5 hours.
Disclosures of Relationships with Ineligible Companies Policy
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.
Planners’ and Managers’ Disclosures
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
All relevant relationships have been reviewed and mitigated.
Kamatham A. Naidu, PhD (MedNet), has no relevant financial relationships to disclose.
Brian Waggoner (MedNet) has no relevant financial relationships to disclose.
Justin Kaiser (Amedco) has no relevant financial relationships to disclose.
Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.
Faculty

Gary Small, MD
Chair of Psychiatry, Hackensack University Medical Center
Behavioral Health Physician-in-Chief
Hovnanian Foundation Chair
Hackensack Meridian Health
Professor and Chair of Psychiatry & Behavioral Health
Hackensack Meridian School of Medicine
Hackensack, NJ

Paul Schulz, MD
Rick McCord Professor in Neurology,
Umphrey Family Professor of Neurodegenerative Disorders,
Director, Memory Disorders and Dementia Clinic,
Director, Neuropsychiatry and Behavioral Neurology Fellowship,
The McGovern Medical School of UTHealth
Houston, TX
Instructions/Technical Requirements

A desktop or laptop computer or a mobile device with a stable internet connection and audio capability is required to attend. Joining via mobile or tablet is possible but not recommended.
Times in the portal adjust to your computer; however, some browsers have a separate time zone adjustment.
For the best viewing experience, we recommend the following browsers: Chrome, Firefox, and Safari. For attendees viewing on Internet Explorer 11, you may experience lags in streaming. To maximize your attendee hub experience, we recommend you not sign in through your company assigned VPN.
Ensure that your computer’s sound is enabled for your browser and allow permissions to the On24 Attendee Hub platform if necessary.

Cost
Complimentary
Contact
Brian Waggoner
Program Manager
MedNet
brianw@mmhus.net

Glaucoma Management: Understanding Risk Factors, Screening and Treatment Options
2024-04-27
April 27, 2024

Take Me to the Event Registration

EVENT Summary
Dates
Saturday, April 27, 2024, 10:00 AM ET/9:00 AM CT
Location
Virtual
Target Audience
Ophthalmologists, optometrists, retina specialists, and advanced practice providers (physician assistants and nurse practitioners)
Format
Zoom Webinar
Credits
1.50 / AMA PRA Category 1 Credit(s)TM
1.50 / COPE CE Credits
Cost
Free
Program Description
Click to Go to the Event Registration
The activity will focus on:
• Pathophysiology of Glaucoma – The balance between the secretion of aqueous humor by the ciliary body and its drainage through 2 independent pathways—the trabecular meshwork and uveoscleral outflow pathway—influences the IOP.
• Risk factors and Screening – Risk factors such as family history, ethnic origin, and age play an important role in screening. Screening of high-risk groups increased the positive predictive value of screening tests.
• Available Treatment Options for glaucoma – Treatment comprises topical agents, either as monotherapy or combination therapy.
• New Treatments to Improve Patient Outcomes – New sustained-release drug delivery systems in treating glaucoma.
• Inequities in Treating Glaucoma – The prevalence of glaucoma is high in African-American and Hispanic patients. Efforts should be placed to educate and train to expand better diagnostic and treatment options.
Agenda

Overview of the risk factors, screening, current, and emerging therapies for glaucoma – David S. Friedman, MD, PhD, MPH
Discuss inequities in the diagnosis and management of glaucoma in African-American and Hispanic populations – Karen Allison, MD, PC

Intended Audience
Ophthalmologists, optometrists, retina specialists, and advanced practice providers (physician assistants and nurse practitioners)
Commercial Supporter
Supported by an educational grant from Alcon Vision.
Learning Objectives

Summarize the pathophysiology, risk factors, and screening of glaucoma
Assess clinical trial data on topical agents in the management of glaucoma
Appraise clinical trial data on sustained-release drug delivery systems in the management of glaucoma
Analyze inequities in the diagnosis and management of glaucoma in African-American and Hispanic patients

Accredited Providers
Amedco and MedNet have collaborated to design and execute this activity.

Physicians (ACCME) Credit

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.

Designation Statement
Amedco LLC designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Optometrists

Accreditation Statement
Amedco is accredited by COPE to provide continuing education to optometrists.

Designation Statement
Amedco designates this activity for a maximum of 1.50 COPE credits.

Additional Credit Information
Physician Assistants
PAs may claim a maximum of 1.50 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. 1.5 hours.
Disclosures of Relationships with Ineligible Companies Policy
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.
Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.
Faculty

Karen Allison, MD, PC
Associate Professor of Clinical Ophthalmology
Department of Ophthalmology (SMD)
University of Rochester
Rochester, NY

David Friedman, MD, PhD, MPH
Ophthalmologist
Director, Glaucoma Service
Albert and Diane Kaneb Chair in Ophthalmology
Medical Director for Clinical Research at Mass. Eye and Ear
Boston, MA
Instructions/Technical Requirements

A desktop or laptop computer or a mobile device with a stable internet connection and audio capability is required to attend. Joining via mobile or tablet is possible but not recommended.
Times in the portal adjust to your computer; however, some browsers have a separate time zone adjustment.
For the best viewing experience, we recommend the following browsers: Chrome, Firefox, and Safari. For attendees viewing on Internet Explorer 11, you may experience lags in streaming. To maximize your attendee hub experience, we recommend you not sign in through your company assigned VPN.
Ensure that your computer’s sound is enabled for your browser and allow permissions to the On24 Attendee Hub platform if necessary.

Cost
Complimentary
Contact
Brian Waggoner
Program Manager
MedNet
brianw@mmhus.net

New Prospects in Blood-based Biomarkers and Disease-Modifying Anti-Amyloid Antibody Therapies for Early-Stage Alzheimer’s Disease
2024-02-10 - 2025-02-10
February 10, 2024

Take Me to the Event Registration

EVENT Summary
Dates
Saturday, February 10, 2024, 11:00 AM ET, 10:00 AM CT, and 9:00 AM MT
Location
Virtual
Target Audience
Neurologists, nurse practitioners, and physician assistants involved in Alzheimer’s disease patient care.
Format
Zoom Webinar
Credits
1.50 / AMA PRA Category 1 Credit(s)TM
Cost
Free
Program Description
Click to Go to the Event Registration
This webinar provides an update on the blood-based markers (BBMs) improve randomized clinical trials (RCTs) design and conduct of Alzheimer’s disease. It remains to be determined if the data available on BBMs are strong enough to replace CSF and PET biomarkers as entry criteria and monitoring tools in RCTs. Strategies to optimize and guide disease-modifying anti-amyloid antibody (AAA) therapies based on BBMs in managing patients with early-stage AD.
Agenda

Discuss the blood-based biomarkers in diagnosing early-stage Alzheimer’s disease (AD) and its utility in the prevention – Jeremy Pruzin, MD
Discuss clinical trial data on safety-efficacy profiles of approved and investigational disease-modifying anti-amyloid antibody therapies in managing early AD – Marwan Sabbagh, MD

Intended Audience
Neurologists, nurse practitioners, and physician assistants involved in Alzheimer’s disease patient care.
Commercial Supporter
Supported by an educational grant from Eisai, Inc.
Learning Objectives

Summarize the pathophysiology and the clinical presentation of Alzheimer’s disease (AD).
Assess the blood-based biomarkers in diagnosing early-stage AD and its utility in the prevention.
Identify strategies to optimize disease-modifying anti-amyloid antibody (AAA) therapies in managing patients with early-stage AD.

Accredited Providers
Amedco and MedNet have collaborated to design and execute this activity.

Physicians (ACCME) Credit

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.

Designation Statement
Amedco LLC designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Credit Information
Physician Assistants
PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. 1.5 hours.
Disclosures of Relationships with Ineligible Companies Policy
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.
Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.
Faculty

Jeremy Pruzin, MD
Behavioral Neurologist
Banner Alzheimer’s Institute
Tucson, AZ

Marwan Sabbagh, MD
Professor of Neurology
Barrow Neurological Institute
Phoenix, AZ
Instructions/Technical Requirements

A desktop or laptop computer or a mobile device with a stable internet connection and audio capability is required to attend. Joining via mobile or tablet is possible but not recommended.
Times in the portal adjust to your computer; however, some browsers have a separate time zone adjustment.
For the best viewing experience, we recommend the following browsers: Chrome, Firefox, and Safari. For attendees viewing on Internet Explorer 11, you may experience lags in streaming. To maximize your attendee hub experience, we recommend you not sign in through your company assigned VPN.
Ensure that your computer’s sound is enabled for your browser and allow permissions to the On24 Attendee Hub platform if necessary.

Cost
Complimentary
Contact
Brian Waggoner
Program Manager
MedNet
brianw@mmhus.net

Glaucoma: Sustained-release Drug Delivery System, Topical Agents, and Emerging 3D Visualization Technologies
2023-03-01 08:00 - 2024-03-01 17:00
CME | CNE 1.00 Credit

Webcast
Time to Complete: 1 hour
Released: March 1, 2023
Expires: March 1, 2024
Maximum Credits:
1.00 / AMA PRA Category 1 CreditTM
1.00 / ANCC Contact Hour
Program Description
Glaucoma is a heterogeneous group of diseases that has become a significant cause of irreversible blindness worldwide. A glaucoma group of optic neuropathies is characterized by progressive degeneration of retinal ganglion cells. These are central nervous system neurons with cell bodies in the inner retina and axons in the optic nerve. Degeneration of these nerves results in cupping, a characteristic optic disc appearance, and visual loss. The biological basis of glaucoma is poorly understood, and the factors contributing to its progression have not been fully characterized.
Intended Audience
This webcast is designed to meet the educational needs of ophthalmologists, optometrists, retina specialists, advanced practice providers, and nurses caring for a patient with glaucoma.
Commercial Supporter
This activity is supported by an educational grant from Alcon Vision, LLC.

Educational Objectives
Upon completion of the educational activity, participants should be able to:

Summarize the pathophysiology of glaucoma development
Assess clinical trial data on new sustained-release drug delivery systems and topical agents in the management of glaucoma
Appraise the utility of 3D visualization in glaucoma surgery

Accredited Providers
This activity is provided by Amedco, a CME/CE company, and MedNet.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physicians (ACCME) Credit Designation
Designation Statement
Amedco LLC designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses (ANCC) Credit Designation
Designation Statement
Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hour.
Additional Credit Information
Note to Physician Assistants
PAs may claim a maximum of 1.00 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit(s)TM from organizations accredited by ACCME or a recognized state medical society
Note to Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allows reciprocity for AANPCP continuing education credit for a maximum of 1.00 hour.
Conflicts of Interest Policy
It is the policy of the Amedco to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.
Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.
Planners’ and Managers’ Disclosures
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:
Kamatham A. Naidu, PhD (MedNet) has no relevant financial relationships.
Brian Waggoner (MedNet) has no relevant financial relationships to disclose.
Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
It is the policy of the Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.
Disclaimer
The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Non-Endorsement of Products
Amedco do not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.
Faculty
Robert Chang, MD
Associate Professor of Ophthalmology
Stanford University
Palo Alto, CA
Dr. Chang discloses the following:
Research support: Alcon and Genentech
Consultant: Alcon, Genentech, 1800 Contacts, Verana Heath, Sight Sciences, Ocular Therapeutix, Apple, and Belken
Advisor: Smartlens and XP Health
SPV: Iantrek
Felipe A Medeiros, MD, PhD
Joseph AC Wadsworth Distinguished Professor of Ophthalmology
Professor of Electrical and Computer Engineering, and Biostatistics
Duke University, Durham, NC
Dr. Medeiros discloses the following:
Research support: National Eye Institute R01 EY029885, R43 EY027651, Carl-Zeiss Meditec, Inc., Heidelberg Engineering, GmBH, Reichert, and Google, Inc.
Consultant: Allergan, Inc., Novartis, Inc., Reichert; , Carl-Zeiss, Inc., Galimedix, Biogen, Stealth Therapeutics, Annexon
Instructions
There are no fees for participating and receiving CME/CE credit for this webcast. During the period from March 1, 2023, through March 1, 2024, participants must read all the material and study the educational webcast.
This webcast includes text, graphics, and may include multimedia features.
In order to receive CME/CE credits, participants must complete the pre-assessment questions, post-assessment, and program evaluation. Participants must also score at least 75% on the post-assessment. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Dashboard or Transcript, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact the CME/CE Provider at certificate@amedcoemail.com.
Privacy Policy
Amedco observes privacy and confidentiality of CME/CE information and personal information of CME/CE participants. Third parties receive only aggregated data about CME/CE activities that are relevant to their interests and/or the activities they support.
myCME privacy policy

New Paradigms in the Clinical Practice of Inflammatory Bowel Diseases - Live Event
2022-11-30
November 30, 2022

Take Me to the Event Registration

EVENT Summary
Dates
Wednesday, November 30, 2022, 7:00 PM EDT
Location
Virtual
Target Audience
Gastroenterologists, internal medicine specialists, primary care physicians, nurse practitioners, physician assistants, and nurses caring for patients with inflammatory bowel diseases (IBDs)
Format
Live Webinar
Credits
1.25 / AMA PRA Category 1 Credit(s)TM
1.25 / ANCC Contact Hours
Cost
Free
Program Description
Click to Go to the Event Registration
Inflammatory bowel diseases (IBD), commonly categorized as Crohn’s disease (CD) and ulcerative colitis (UC), are immune mediated chronic inflammatory disorders of the gastrointestinal tract. The etiopathogenesis is multifactorial, with different environmental, genetic, immune mediated, and gut microbial factors playing an important role. The current therapy goals are to improve clinical symptoms, control inflammation, prevent complications, and improve quality of life. Different therapeutic agents are available with their indications, mechanisms of action, and side effects. The field of IBD therapeutics has seen tremendous improvements, and the efficacy of new drug targets such as IL-12/IL-23, the JAK/STAT pathway, and S1P has been established.
Agenda

Role of the drug targets such as S1P, the JAK/STAT, the IL-12/IL-23 pathway, and biosimilars in managing IBD – Miguel Regueiro, MD
Case Presentation 1 – Miguel Regueiro, MD
Discuss the interdisciplinary management of extra-intestinal manifestations in people living with IBD – Francis Farraye, MD
Case Presentation 2 – Farraye, MD
Q&A from the Audience and Panel Discussion – Miguel Regueiro, MD/Francis Farraye, MD

Intended Audience
Gastroenterologists, internal medicine specialists, primary care physicians, nurse practitioners, physician assistants, and nurses caring for patients with inflammatory bowel diseases (IBDs).
Commercial Supporters
Supported by educational grants from Pfizer Inc. and Bristol Myers Squibb.
Learning Objectives

Incorporate biologics, small molecule inhibitors, and biosimilars in the treatment of inflammatory bowel diseases (IBD)
Assess the interdisciplinary management strategies of extra-intestinal manifestations in people living with IBD

Accredited Providers
Jointly provided by Amedco, a CME/CE company, and MedNet

Joint Accreditation

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MEDNET. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians (ACCME) Credit
Designation Statement
Amedco LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses (ANCC) Credit
Designation Statement
Amedco LLC designates this activity for a maximum of 1.25 ANCC contact hours.
Additional Credit Information
Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 1.25 hours.
Physician Assistants
AAPA accepts AMA PRA Category 1 Credit(s)TM for the PRA from organizations accredited by ACCME. Maximum of 1.25 hours.
Staff Disclosures
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Kamatham A. Naidu, PhD (MedNet) has no relevant financial relationships.
Brian Waggoner (MedNet) has no relevant financial relationships to disclose.
Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.

Faculty

Miguel Regueiro, MD
Professor, Department of Medicine
Chair, Digestive Disease and Surgery Institute
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, OH

Francis Farraye, MD
Professor of Medicine
Director, Inflammatory Bowel Disease Center
Division of Gastroenterology and Hepatology
Mayo Clinic
Jacksonville, Florida
Instructions/Technical Requirements

A desktop or laptop computer with a stable internet connection and audio capability is required to attend. Joining via mobile or tablet is possible but not recommended.
Times in the portal adjust to your computer; however, some browsers have a separate time zone adjustment.
For the best viewing experience, we recommend the following browsers: Chrome, Firefox, and Safari. For attendees viewing on Internet Explorer 11, you may experience lags in streaming. To maximize your attendee hub experience, we recommend you not sign in through your company assigned VPN.
Ensure that your computer’s sound is enabled for your browser and allow permissions to the On24 Attendee Hub platform if necessary.

Cost
Complimentary
Contact
Brian Waggoner
Program Manager
MedNet
brianw@mmhus.net
